Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, achieving significant symptom reduction and demonstrating a novel CAR T-cell approach.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

New treatment options for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could enhance patient care and monitoring.

Mirvetuximab soravtansine, particularly in combination regimens, showed promising efficacy and an acceptable safety profile in recurrent ovarian cancer.